Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on October 15, 2025. The filing was submitted on October 16, 2025. The transaction was executed through BNP Paribas SA as part of the Company's existing share buyback programme, pursuant to a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing details the repurchase of ordinary shares rather than operational financial results. Key metrics for the transaction are as follows:
- Shares Purchased (Oct 15, 2025): 405,500 ordinary shares.
- Price Range: Lowest price paid was 1,608.00 GBp; highest price paid was 1,633.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,617.97 GBp.
- Programme Progress: Since September 30, 2025, the Company has purchased a total of 3,919,500 ordinary shares.
- Treasury Holdings: Following this purchase, the Company holds 251,384,344 ordinary shares in treasury.
- Shares in Issue: 4,064,029,485 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.19% of the total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock due to the buyback activity. The filing does not provide comparative financial data (revenue, profit, or cash flow) against prior periods, as it is a disclosure of a specific capital transaction rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risks are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares held in treasury (251,384,344) against the latest Form 20-F or quarterly reports.
- Confirm the remaining capacity under the existing buyback programme announced on September 30, 2025.
- Review the "Risk Factors" in the 2024 Form 20-F and Q2 2025 results for context on the forward-looking statement disclaimer.
- Check the denominator for voting rights calculations (4,064,029,485) for compliance with FCA Disclosure Guidance and Transparency Rules.